Efficacy of a recombinant amino terminal fragment of bactericidal/permeability increasing protein in rodents challenged with LPS or E. coli bacteria.
Kung
A H
AH
Department of Pharmacology and Toxicology, XOMA Corporation, Berkeley, CA 94710.
Ammons
W S
WS
Lin
Y
Y
Kohn
F R
FR
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides; D016470:Bacteremia / Q000150:complications / Q000188:drug therapy; D001770:Blood Bactericidal Activity; D001798:Blood Proteins / Q000494:pharmacology*; D004195:Disease Models, Animal; D004927:Escherichia coli Infections / Q000150:complications / Q000188:drug therapy; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D008565:Membrane Proteins; D051379:Mice; D008813:Mice, Inbred ICR; D010446:Peptide Fragments / Q000494:pharmacology*; D010538:Peritonitis / Q000150:complications / Q000188:drug therapy; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D018746:Systemic Inflammatory Response Syndrome / Q000209:etiology / Q000517:prevention & control*; D014115:Toxemia / Q000150:complications / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D001798:Blood Proteins; D008070:Lipopolysaccharides; D008565:Membrane Proteins; D010446:Peptide Fragments; D011994:Recombinant Proteins; C021623:bactericidal permeability increasing protein